Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:FDA |
| gptkbp:ATCCode |
L01XE28
|
| gptkbp:brand |
gptkb:Zykadia
|
| gptkbp:CASNumber |
1032900-25-6
|
| gptkbp:chemicalFormula |
C28H36N5O3Cl
|
| gptkbp:contraindication |
hypersensitivity to ceritinib
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
41 hours
|
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:ceritinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zykadia
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:mechanismOfAction |
ALK inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
97.1%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue increased liver enzymes |
| gptkbp:target |
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
| gptkbp:bfsParent |
gptkb:ceritinib
|
| gptkbp:bfsLayer |
6
|